We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+5.26%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$24B
AUM Growth
+$1.05B
(+4.6%)
Cap. Flow
-$221M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
13.73%
Holding
1,494
New
103
Increased
612
Reduced
406
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$114M |
| 2 |
AET
Aetna Inc
AET
|
+$96.3M |
| 3 |
Travelers Companies
TRV
|
+$94.5M |
| 4 |
CHK
Chesapeake Energy Corporation
CHK
|
+$89M |
| 5 |
Ameren
AEE
|
+$69.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deutsche Bank
DB
|
+$247M |
| 2 |
Verizon
VZ
|
+$186M |
| 3 |
Medtronic
MDT
|
+$150M |
| 4 |
LO
LORILLARD INC COM STK
LO
|
+$126M |
| 5 |
Johnson Controls International
JCI
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.44% |
| 2 | Technology | 14.68% |
| 3 | Financials | 12.75% |
| 4 | Industrials | 11.1% |
| 5 | Energy | 9.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSGS
501
DELISTED
CSG Systems International
CSGS
| $5.74M | 0.02% |
220,000
-34,814
| -14% | -$906K |
|
502
Huntington Ingalls Industries
HII
$11B
| $5.73M | 0.02% |
60,600
+31,140
| +106% | +$3.11M |
|
503
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.5B
| $5.6M | 0.02% |
110,840
+11,840
| +12% | +$579K |
|
504
Targa Resources
TRGP
$61.3B
| $5.58M | 0.02% |
40,000
+5,000
| +14% | +$575K |
|
505
SM Energy
SM
$9.82B
| $5.55M | 0.02% |
66,000
+31,000
| +89% | +$2.38M |
|
506
iShares China Large-Cap ETF
FXI
$4.1B
| $5.54M | 0.02% |
149,650
+11,860
| +9% | +$430K |
|
507
State Street SPDR S&P 500 ETF Trust
SPY
$799B
| $5.51M | 0.02% |
28,142
-19,848
| -41% | -$3.77M |
|
|
SPNC
508
DELISTED
Spectranetics Corp
SPNC
| $5.46M | 0.02% |
238,733
+47,536
| +25% | +$1.1M |
|
|
ELGX
509
DELISTED
Endologix Inc
ELGX
| $5.45M | 0.02% |
35,810
-722
| -2% | -$96.1K |
|
|
SRCI
510
DELISTED
SRC Energy Inc
SRCI
| $5.43M | 0.02% |
410,000
+50,000
| +14% | +$578K |
|
511
Neurocrine Biosciences
NBIX
$15.2B
| $5.37M | 0.02% |
362,145
+54,677
| +18% | +$772K |
|
512
PTC
PTC
$14.4B
| $5.35M | 0.02% |
138,000
+8,000
| +6% | +$288K |
|
|
NUVA
513
DELISTED
NuVasive, Inc.
NUVA
| $5.33M | 0.02% |
149,989
-6,282
| -4% | -$215K |
|
514
M&T Bank
MTB
$34B
| $5.31M | 0.02% |
42,800
+15,200
| +55% | +$1.85M |
|
515
Chubb
CB
$132B
| $5.3M | 0.02% |
51,104
-1,161
| -2% | -$119K |
|
516
Radware
RDWR
$1.25B
| $5.3M | 0.02% |
314,000
+14,000
| +5% | +$236K |
|
517
Clorox
CLX
$10.5B
| $5.3M | 0.02% |
57,951
+20,513
| +55% | +$1.84M |
|
|
EMES
518
DELISTED
Emerge Energy Services LP
EMES
| $5.29M | 0.02% |
+50,000
| New | +$4.34M |
|
519
Matador Resources
MTDR
$7.82B
| $5.27M | 0.02% |
180,000
+5,000
| +3% | +$132K |
|
|
BNY
520
Bank of New York Mellon
BNY
$105B
| $5.25M | 0.02% |
140,034
+1,880
| +1% | +$65K |
|
|
HTWR
521
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $5.25M | 0.02% |
59,297
+11,851
| +25% | +$1.06M |
|
522
SBA Communications
SBAC
$19.4B
| $5.18M | 0.02% |
50,610
-9,297
| -16% | -$892K |
|
523
Graco
GGG
$12.4B
| $5.14M | 0.02% |
197,655
+90,726
| +85% | +$2.24M |
|
524
EnerSys
ENS
$6.15B
| $5.06M | 0.02% |
73,500
-1,083
| -1% | -$73.6K |
|
525
Molson Coors Class B
TAP
$7.32B
| $5.04M | 0.02% |
68,000
+18,700
| +38% | +$1.2M |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q2 2014 Portfolio in Review
As of Q2 2014, Axa held 1,494 positions worth $24B, up 4.6% from $23B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Axa's Q2 2014 filing shows 103 new, 612 increased, 406 reduced and 115 closed positions. Its largest new stake was Boston Scientific: 4,394,250 shares worth $56.1M. The largest sale was Deutsche Bank, an estimated $247M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Technology and Financials.
- Axa's largest Q2 2014 buy was Boston Scientific: 4,394,250 shares worth $56.1M.
- Axa added most to Gilead Sciences in Q2 2014, an estimated $114M increase.
- Axa's biggest Q2 2014 reduction was Deutsche Bank, cutting an estimated $247M.
- Axa fully exited OMNICARE INC in Q2 2014, selling an estimated $20.4M.
- Axa's ten largest holdings make up 14% of its $24B portfolio in Q2 2014.
- Axa opened 103 new positions and closed 115 in Q2 2014.
- Axa's portfolio value rose 4.6% quarter-over-quarter to $24B.
Based on Axa's 13F filing for Q2 2014, filed 13 Aug 2014.